DCISionRT

A risk assessment test for women diagnosed with DCIS.

What is DCISionRT?

Icon Cancer Centre provides access to the DCISionRT test; an important precision medicine tool for patients diagnosed with Ductal Carcinoma In Situ (DCIS) post core biopsy or lumpectomy.

Ductal carcinoma in situ (DCIS) is the presence of abnormal cells inside a milk duct in one or both breasts. DCIS is considered the earliest form of breast cancer and is sometimes referred to as Stage 0 (zero). DCIS is noninvasive, meaning it has not spread out from the milk duct and has a lower risk of progressing to invasive breast cancer.

DCISionRT is a risk assessment test for women diagnosed with DCIS. DCISionRT evaluates a patient’s individual biology along with other risk factors to provide a personalised risk assessment. It predicts the risk of a future DCIS or invasive breast cancer recurrence in that same breast over the next 10 years. It also predicts the benefit from radiotherapy in reducing the risk of DCIS or invasive disease recurring.

Upon confirming clinical eligibility, Icon will arrange the DCISionRT test for you. Results will typically be available within ten business days. Test results will be sent directly to your doctor. No additional biopsy or surgery is required. A follow up appointment will be made to discuss the recommended treatment based on the test results.